Ind-Swift Laboratories Limited

NSEI:INDSWFTLAB Stock Report

Market Cap: ₹6.1b

Ind-Swift Laboratories Valuation

Is INDSWFTLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INDSWFTLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INDSWFTLAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INDSWFTLAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INDSWFTLAB?

Key metric: As INDSWFTLAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for INDSWFTLAB. This is calculated by dividing INDSWFTLAB's market cap by their current earnings.
What is INDSWFTLAB's PE Ratio?
PE Ratio1.6x
Earnings₹3.73b
Market Cap₹6.15b

Price to Earnings Ratio vs Peers

How does INDSWFTLAB's PE Ratio compare to its peers?

The above table shows the PE ratio for INDSWFTLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.7x
ACCENTMIC Accent Microcell
15.5xn/a₹5.2b
NECLIFE Nectar Lifesciences
71.7xn/a₹7.8b
524731 Jenburkt Pharmaceuticals
16.4xn/a₹5.3b
541400 ZIM Laboratories
31.2xn/a₹5.1b
INDSWFTLAB Ind-Swift Laboratories
1.6xn/a₹6.1b

Price-To-Earnings vs Peers: INDSWFTLAB is good value based on its Price-To-Earnings Ratio (1.6x) compared to the peer average (33.7x).

Price to Earnings Ratio vs Industry

How does INDSWFTLAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.32.2x17.8%
INDSWFTLAB Ind-Swift Laboratories
 1.6xn/aUS$72.78m
524652 Ind-Swift
2xn/aUS$13.52m
No more companies available in this PE range
INDSWFTLAB 1.6xIndustry Avg. 32.2xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
Industry Avg.32.2x17.8%
INDSWFTLAB Ind-Swift Laboratories
 1.6xn/aUS$72.78m
No more companies

Price-To-Earnings vs Industry: INDSWFTLAB is good value based on its Price-To-Earnings Ratio (1.6x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is INDSWFTLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INDSWFTLAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate INDSWFTLAB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

7D

-1.3%

1Y

-16.9%